<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02869100</url>
  </required_header>
  <id_info>
    <org_study_id>2012-A00568-35</org_study_id>
    <nct_id>NCT02869100</nct_id>
  </id_info>
  <brief_title>Comparison of Sodium Fluoride Positron Emission Tomography and Magnetic Resonance Imaging of Spine and Sacroiliac Joints for Detection of Inflammatory Lesions in Spondyloarthritis Patients</brief_title>
  <acronym>FNa</acronym>
  <official_title>Comparison of Sodium Fluoride Positron Emission Tomography and Magnetic Resonance Imaging of Spine and Sacroiliac Joints for Detection of Inflammatory Lesions in Patients Affected by Spondyloarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to compare detection of axial inflammatory lesions in patients affected by
      spondyloarthritis (SpA) with sodium fluoride positron emission tomography (PET) and magnetic
      resonance imaging (MRI), the reference technique.

      It would be interesting to show the superiority of sodium fluoride PET on MRI for diagnosis
      of inflammatory lesions. It could be used for diagnostic care but also therapeutic care of
      patients with early forms of spondyloarthritis.

      Secondary purposes are:

        -  To evaluate performances of sodium fluoride PET in detection of SpA peripheral damage
           (except spine and sacroiliac joints)

        -  To evaluate bone inflammation (axial and peripheral) with sodium fluoride PET and
           compare these data to clinic-biologic parameters used in clinical practice (BASDAI,
           BASFI, BASMI, sedimentation rate, C-reactive protein (CRP)) and to structural evaluation
           (sacroiliac New York, mSASSS and BASRI scoring methods)

        -  To study correlation of axial and peripheral bone inflammation (spine and sacroiliac
           joints) evaluated with sodium fluoride PET with biologic markers of inflammation and
           bone remodeling (MMP-3; DKK-1, IL-6, IL-17, TNF-α).

      Known biologic markers of inflammation in SpA are correlated to activity obtained with MRI.
      It is interesting to compare to activity obtained with PET. Moreover, it has been recently
      showed the disassociation of inflammation and structural progression (anti-TNF treatments do
      not prevent structural progression) that is associated to markers of bone remodeling whose
      activity is influenced by an activation/inhibition system of biologic markers of
      inflammation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concordance between binary topographic evaluations of bone inflammation in PET data and MRI data</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>presence or absence of inflammatory sites (MRI) or hyperfixation (PET) in 28 sites (24 vertebrae and 4 sacroiliac joints)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concordance between semi-quantitative evaluation of bone inflammation in MRI data and PET data</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>PET: BME score adapted to PET for spine and modified SPARCC score adapted to PET for sacroiliac joints
MRI: Berlin score BME for spine and SPARCC score for sacroiliac joints</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Structural evaluation with New York score</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Structural evaluation with mSASSS scores</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Structural evaluation with BASRI score</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of specific biologic markers of inflammation and bone remodeling in blood</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>MMP-3, DKK-1, IL-6, IL-17, TNF-α</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard biologic evaluation of sedimentation rate</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard biologic evaluation of C-reactive protein</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of spinal mobility with BASMI index</measure>
    <time_frame>up to 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of disease activity with BASDAI index</measure>
    <time_frame>up to 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of functional impact with BASFI index</measure>
    <time_frame>up to 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Spondyloarthritis</condition>
  <arm_group>
    <arm_group_label>Spondyloarthritis Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <arm_group_label>Spondyloarthritis Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sodium fluoride Positron Emission Tomography</intervention_name>
    <arm_group_label>Spondyloarthritis Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <arm_group_label>Spondyloarthritis Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Radiography</intervention_name>
    <arm_group_label>Spondyloarthritis Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-50 year-old patients affected by axial or mixed SpA (ASAS criteria) or &gt;18 year-old
             patients according to New York criteria

          -  Patients with bone marrow edema lesions in sacroiliac joints and/or spine detected
             with MRI

          -  No therapeutic changes between hospitalization for evaluation of SpA activity and
             inclusion visit

          -  Informed consent

          -  Affiliation to social security plan

        Exclusion Criteria:

          -  Refusal or impossibility of signed informed consent

          -  Doubt about possible pregnancy in women of childbearing potential

          -  Pregnancy and breastfeeding

          -  History of drug addiction, alcoholism, psychological problems, severe co-morbidities

          -  Renal insufficiency (creatinine clearance &lt; 60 ml/min)

          -  Juridical protection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre OLIVIER, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nancy, Hôpitaux de Brabois, service de Médecine Nucléaire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Nancy, Hôpitaux de Brabois</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2016</study_first_submitted>
  <study_first_submitted_qc>August 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2016</study_first_posted>
  <last_update_submitted>August 11, 2016</last_update_submitted>
  <last_update_submitted_qc>August 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>magnetic resonance imaging</keyword>
  <keyword>sodium fluoride positron emission tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorides</mesh_term>
    <mesh_term>Sodium Fluoride</mesh_term>
    <mesh_term>Listerine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

